DCP
BNTX icon

Davern Capital Partners’s BioNTech BNTX Stock Holding History

Davern Capital Partners’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.2M Buy
754,550
+449,495
+147% +$42.3M 11.97% 1
2026
Q1 		$27.1M Sell
305,055
-66,161
-18% -$6.8M 7.44% 6
2025
Q4 		$35.3M Buy
+371,216
New +$37.4M 11.43% 3

Other funds holding BNTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
GP
GSK plc London $602M AUM

Davern Capital Partners's BNTX Position: Q2 2026 in Review

Davern Capital Partners increased its BioNTech (BNTX) stake by 147% in Q2 2026, buying an estimated $42.3M and bringing the position to 754,550 shares worth $70.2M. The position accounts for 11.97% of the portfolio, ranked #1.

Davern Capital Partners first reported a position in BNTX in Q4 2025 and has held it in 3 quarters since. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

  • Davern Capital Partners held 754,550 shares of BioNTech worth $70.2M as of Q2 2026.
  • Davern Capital Partners bought 449,495 BioNTech shares in Q2 2026, an estimated $42.3M.
  • BioNTech made up 11.97% of Davern Capital Partners's portfolio in Q2 2026, its #1 holding.
  • Davern Capital Partners first reported a position in BioNTech in Q4 2025 and has held it in 3 quarters since.
  • 282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Davern Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.